Defence Therapeutics Inc.

Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer

2026-08-04 03:15:00

Montreal, Quebec--(Newsfile Corp. - August 4, 2026) -  Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President and Chief Executive Officer, effective August 1, 2026. As part of the leadership transition, Mr.

Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

2026-07-08 03:15:00

Montreal, Quebec--(Newsfile Corp. - July 8, 2026) -   Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario, supporting the Company's expanding radiopharmaceutical research and business development activities. Hamilton has emerged as one of Canada's leading hubs for radiopharmaceutical innovation, bringing together world-class capabilities spanning isotope production, radiopharmaceutical discovery, translational research, GMP manufacturing, and clinical translation.

Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions

2026-06-17 03:15:00

Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California. Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, and potential strategic collaborators interested in exploring partnership opportunities involving Defence's proprietary Accum® platform.

Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

2026-06-03 03:15:00

Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations.

Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors

2026-06-01 03:15:00

Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), further strengthening Defence's strategic capabilities as the Company advances its ACCUM®-enabled ADC platform and partnership programs.

Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian

2026-05-29 16:30:00

Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)  ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today from the Board of Directors of Defence to deepen engagement with the Company by joining the Scientific Advisory Board ("SAB"). Defence Therapeutics' current SAB is composed of Rob Leanna, PhD, Danny Chui, PhD and Brendan Hussey, PhD.

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

2026-05-19 03:15:00

Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs.